TY - JOUR
T1 - Perceptions, attitudes and barriers to obesity management
T2 - Japanese data from the ACTION-IO study
AU - Iwabu, Masato
AU - Yamauchi, Toshimasa
AU - Shimomura, Iichiro
AU - Eguchi, Kosei
AU - Ogawa, Yoshihiro
N1 - Funding Information:
This study was sponsored by Novo Nordisk, which also provided financial support for medical editorial assistance from Bhavika Modasia PhD and Ege Yildirim PhD, of Articulate Science. KE is an employee of Novo Nordisk Pharma Ltd. MI and TY are employees of the Department of Diabetes and Metabolic Diseases at The University of Tokyo. MI is a member of the ACTION-IO study steering committee, and reports industrial links with Novo Nordisk. TY reports industrial links with AeroSwitch, Asahi Mutual Life Insurance Company, Astellas Pharma, AstraZeneca K.K., Boehringer Ingelheim, Daiichi Sankyo, Dojindo Molecular Technologies, Eli Lilly and Company, FUJIFILM Toyama Chemical, Johnson & Johnson, Kissei Pharmaceutical, Kowa Pharmaceutical, Kyowa Kirin, Medtronic Japan (formerly Covidien Japan), Merck & Co., Mitsubishi Corporation Life Sciences, Mitsubishi Tanabe Pharma, Nippon Becton Dickinson, Nipro Corporation, Novartis International AG, Novo Nordisk Pharma Ltd., NTT DOCOMO, Ono Pharmaceutical, Sanofi S.A., Sanwa Kagaku Kenkyusho, Shionogi & Co., Sumitomo Dainippon Pharma, Taisho Pharmaceutical, Takeda Pharmaceutical and Tosoh Corporation. IS is an employee of the Department of Metabolic Medicine at Osaka University, and reports industrial links with Amgen Astellas BioPharma K.K., Astellas Pharma, AstraZeneca K.K., Daiichi Sankyo, Eli Lilly Japan K.K., KOBAYASHI Pharmaceutical, Kyowa Kirin, Medtronic Japan (formerly Covidien Japan), Mitsubishi Tanabe Pharma, MSD K.K., Nippon Boehringer Ingelheim, Nippon Chemiphar, Novartis Pharma K.K., Ono Pharmaceutical, Rohto Pharmaceutical, Sanofi K.K., Sumitomo Dainippon Pharma, Sanwa Kagaku Kenkyusho, Sumitomo Dainippon Pharma, Taisho Pharmaceutical, Takeda Pharmaceutical and Teijin Pharma. YO is an employee of the Department of Medicine and Bioregulatory Science at Kyushu University, and has no industrial links to disclose.
Funding Information:
This study was sponsored by Novo Nordisk, which also provided financial support for medical editorial assistance from Bhavika Modasia PhD and Ege Yildirim PhD, of Articulate Science. KE is an employee of Novo Nordisk Pharma Ltd. MI and TY are employees of the Department of Diabetes and Metabolic Diseases at The University of Tokyo. MI is a member of the ACTION‐IO study steering committee, and reports industrial links with Novo Nordisk. TY reports industrial links with AeroSwitch, Asahi Mutual Life Insurance Company, Astellas Pharma, AstraZeneca K.K., Boehringer Ingelheim, Daiichi Sankyo, Dojindo Molecular Technologies, Eli Lilly and Company, FUJIFILM Toyama Chemical, Johnson & Johnson, Kissei Pharmaceutical, Kowa Pharmaceutical, Kyowa Kirin, Medtronic Japan (formerly Covidien Japan), Merck & Co., Mitsubishi Corporation Life Sciences, Mitsubishi Tanabe Pharma, Nippon Becton Dickinson, Nipro Corporation, Novartis International AG, Novo Nordisk Pharma Ltd., NTT DOCOMO, Ono Pharmaceutical, Sanofi S.A., Sanwa Kagaku Kenkyusho, Shionogi & Co., Sumitomo Dainippon Pharma, Taisho Pharmaceutical, Takeda Pharmaceutical and Tosoh Corporation. IS is an employee of the Department of Metabolic Medicine at Osaka University, and reports industrial links with Amgen Astellas BioPharma K.K., Astellas Pharma, AstraZeneca K.K., Daiichi Sankyo, Eli Lilly Japan K.K., KOBAYASHI Pharmaceutical, Kyowa Kirin, Medtronic Japan (formerly Covidien Japan), Mitsubishi Tanabe Pharma, MSD K.K., Nippon Boehringer Ingelheim, Nippon Chemiphar, Novartis Pharma K.K., Ono Pharmaceutical, Rohto Pharmaceutical, Sanofi K.K., Sumitomo Dainippon Pharma, Sanwa Kagaku Kenkyusho, Sumitomo Dainippon Pharma, Taisho Pharmaceutical, Takeda Pharmaceutical and Teijin Pharma. YO is an employee of the Department of Medicine and Bioregulatory Science at Kyushu University, and has no industrial links to disclose.
Funding Information:
MI reports receiving non‐financial support from Novo Nordisk during the study, and personal fees from Novo Nordisk outside the submitted work. TY reports receiving grants from AeroSwitch, Asahi Mutual Life Insurance Company, Mitsubishi Corporation Life Sciences, Nipro Corporation, NTT DOCOMO and Tosoh Corporation during the study and outside the submitted work; personal fees from Dojindo Molecular Technologies, Eli Lilly and Company, FUJIFILM Toyama Chemical, Johnson & Johnson, Kissei Pharmaceutical, Medtronic Japan (formerly Covidien Japan) and Nippon Becton Dickinson during the study and outside the submitted work; grants and personal fees from Astellas Pharma, AstraZeneca K.K., Boehringer Ingelheim, Daiichi Sankyo, Kowa Pharmaceutical, Merck & Co., Mitsubishi Tanabe Pharma, Novartis International AG, Novo Nordisk Pharma Ltd., Ono Pharmaceutical, Sanofi S.A., Sanwa Kagaku Kenkyusho, Shionogi & Co, Sumitomo Dainippon Pharma, Taisho Pharmaceutical and Takeda Pharmaceutical during the study; and grants and personal fees from Kyowa Kirin outside the submitted work. IS reports receiving grants, personal fees and non‐financial support from Novo Nordisk Pharma Ltd. during the study; grants from Eli Lilly Japan K.K. and Novartis Pharma K.K. outside the submitted work; personal fees from Amgen Astellas BioPharma K.K., AstraZeneca K.K., KOBAYASHI Pharmaceutical, Medtronic Japan (formerly Covidien Japan), Nippon Boehringer Ingelheim, Nippon Chemiphar, Rohto Pharmaceutical, Sanwa Kagaku Kenkyusho and Taisho Pharmaceutical outside the submitted work; and grants and personal fees from Astellas Pharma, Daiichi Sankyo, Kowa Pharmaceutical, Kyowa Kirin, Mitsubishi Tanabe Pharma, MSD K.K., Ono Pharmaceutical, Sanofi K.K., Sumitomo Dainippon Pharma, Takeda Pharmaceutical and Teijin Pharma outside the submitted work. KE is an employee of Novo Nordisk Pharma Ltd. YO declares no conflict of interest.
Publisher Copyright:
© 2020 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd
PY - 2021/5
Y1 - 2021/5
N2 - Aims/Introduction: The prevalence of obesity is rising in Japan and represents a considerable unmet medical need. The Awareness, Care and Treatment in Obesity MaNagement – International Observation (ACTION-IO) study was designed to identify the perceptions, attitudes and barriers to obesity care among people with obesity (PwO) and healthcare professionals (HCPs) in Japan. Materials and Methods: An online, cross-sectional survey was carried out in 11 countries, including Japan. Results: The survey was completed by 2,001 PwO and 302 HCPs in Japan. Fewer PwO (58%) than HCPs (85%) perceived obesity as a chronic disease. Most PwO (81%) thought that weight loss was their own responsibility, and waited a considerable time before seeking support from their HCP (mean 6 years). Most PwO (64%) had made one or more serious weight loss attempt in the past. In contrast, a serious attempt at losing weight was reported by HCPs for just 21% of their patients. Just 24% of PwO had weight discussions with an HCP in the past 5 years; of those, 56% expressed positive feelings after such a conversation, and just 2% felt offended. Lack of patient motivation (68%) and patient disinterest (61%) were reported by HCPs as barriers to weight management conversations. A higher proportion of obesity specialists (37%) than non-specialists (22%) thought their patients were motivated to lose weight. Conclusions: Our Japanese dataset shows a need to raise awareness of the pathophysiological basis and clinical management of obesity among PwO and HCPs. The largely positive feelings expressed by PwO after weight loss conversations should encourage HCPs to initiate earlier discussions before obesity-related complications occur.
AB - Aims/Introduction: The prevalence of obesity is rising in Japan and represents a considerable unmet medical need. The Awareness, Care and Treatment in Obesity MaNagement – International Observation (ACTION-IO) study was designed to identify the perceptions, attitudes and barriers to obesity care among people with obesity (PwO) and healthcare professionals (HCPs) in Japan. Materials and Methods: An online, cross-sectional survey was carried out in 11 countries, including Japan. Results: The survey was completed by 2,001 PwO and 302 HCPs in Japan. Fewer PwO (58%) than HCPs (85%) perceived obesity as a chronic disease. Most PwO (81%) thought that weight loss was their own responsibility, and waited a considerable time before seeking support from their HCP (mean 6 years). Most PwO (64%) had made one or more serious weight loss attempt in the past. In contrast, a serious attempt at losing weight was reported by HCPs for just 21% of their patients. Just 24% of PwO had weight discussions with an HCP in the past 5 years; of those, 56% expressed positive feelings after such a conversation, and just 2% felt offended. Lack of patient motivation (68%) and patient disinterest (61%) were reported by HCPs as barriers to weight management conversations. A higher proportion of obesity specialists (37%) than non-specialists (22%) thought their patients were motivated to lose weight. Conclusions: Our Japanese dataset shows a need to raise awareness of the pathophysiological basis and clinical management of obesity among PwO and HCPs. The largely positive feelings expressed by PwO after weight loss conversations should encourage HCPs to initiate earlier discussions before obesity-related complications occur.
UR - http://www.scopus.com/inward/record.url?scp=85096684670&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85096684670&partnerID=8YFLogxK
U2 - 10.1111/jdi.13427
DO - 10.1111/jdi.13427
M3 - Article
C2 - 33021048
AN - SCOPUS:85096684670
SN - 2040-1116
VL - 12
SP - 845
EP - 858
JO - Journal of Diabetes Investigation
JF - Journal of Diabetes Investigation
IS - 5
ER -